Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...
In the dynamic environment of small to medium enterprises and startups, leaders often face a barrage of tasks demanding immediate attention. The Eisenhower Matrix, a strategic prioritization tool, ...
TIOBE Index for February 2026: Top 10 Most Popular Programming Languages Your email has been sent February’s TIOBE Index shows a leaderboard that looks steady at first glance, but small shifts beneath ...
Kelly-Ann Franklin has spent more than two decades in journalism which has helped her build a wide knowledge base of business and personal finance topics. Her goal with editing is to ensure tough ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results